Ganitumab (AMG 479) inhibits IGF-II–dependent ovarian cancer growth and potentiates platinum-based chemotherapy

PJ Beltran, FJ Calzone, P Mitchell, YA Chung… - Clinical Cancer …, 2014 - AACR
Purpose: Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the
pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal …
被引用次数：53 相关文章

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

PJ Beltran, FJ Calzone, P Mitchell… - … cancer research: an …, 2014 - escholarship.org
PurposeInsulin-like growth factor 1 receptor (IGF-IR) has been implicated in the
pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal …

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

PJ Beltran, FJ Calzone, P Mitchell… - … Cancer Research: an …, 2014 - europepmc.org
Purpose Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the
pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal …
[HTML] nih.gov

[HTML][HTML] Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

PJ Beltran, FJ Calzone, P Mitchell… - … cancer research: an …, 2014 - ncbi.nlm.nih.gov
Purpose Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the
pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal …

[引用][C] Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

PJ BELTRAN, FJ CALZONE, G YANG… - Clinical cancer …, 2014 - pascal-francis.inist.fr
Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates
Platinum-Based Chemotherapy CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy

PJ Beltran, FJ Calzone, P Mitchell… - Clinical Cancer …, 2014 - pure.johnshopkins.edu
Purpose: Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the
pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal …

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy

PJ Beltran, FJ Calzone, P Mitchell… - … : an official journal …, 2014 - pubmed.ncbi.nlm.nih.gov
Purpose Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the
pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal …

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

PJ Beltran, FJ Calzone, P Mitchell… - … Cancer Research: an …, 2014 - europepmc.org
Purpose Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the
pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal …

[引用][C] Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

PJ BELTRAN, FJ CALZONE… - Clinical …, 2014 - American Association for Cancer …